Confronting the Global Rise of Obesity and Cardiovascular Disease: The Role of GLP-1 RAs
Publication date: 2 December 2025 Source: JACC, Volume 86, Issue 22 Author(s): Erica S. Spatz
GLP-1 users to make up 35% of food and beverage sales by 2030: report
As more consumers take weight loss medications like Ozempic or Wegovy, companies will need to act fast if they want to adapt, according to Circana.
Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials
Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo-controlled phase 3 trials enrolled 3,808 adults ages 55-85 with mild cognitive impairment or mild dementia. Over a two-year period, […]
Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why
We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
NATICK, Mass.–(BUSINESS WIRE)—- $ALUR–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after […]
Pill form of semaglutide fails to slow Alzheimer’s in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced on Nov. 24.
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD – Yahoo
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD Yahoo
GLP-1 Weight-Loss Drug in Pill Form Shows Promise in Trial
By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — New clinical trial results bode well for what could be the first GLP-1…
PrecisionLife and Ovation Partner to Develop Precision Medicine Test to Inform Reimbursement of GLP-1 Anti-Obesity Drugs
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability. OXFORD, England and PORTLAND, ME, Nov. 25, 2025 /PRNewswire/ — Ovation.io, a leading human omics and clinical data…
Two Alzheimer’s Trial Failures Reveal Clinical Challenges
Two major clinical disappointments Johnson & Johnson’s anti-tau antibody and Novo Nordisk’s GLP-1 metabolic therapy underscore just how complex and Alzheimer’s remains.